Hemophilia Care in the New Millennium

  • Dougald M. Monroe
  • Ulla Hedner
  • Maureane R. Hoffman
  • Claude Negrier
  • Geoffrey F. Savidge
  • Gilbert C. WhiteII

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 489)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Infectious Disease Risk

    1. Naomi L. C. Luban, Rima F. Jubran
      Pages 1-12
  3. Unexplained Aspects of Hemophilia and Hemostasis

    1. Michael Kalafatis, Kenneth G. Mann
      Pages 31-43
  4. Novel Approaches to Therapy

    1. P. M. Mannucci, L. Mendolicchio, A. Gringeri
      Pages 59-64
    2. Pete Lollar, John F. Healey, Rachel T. Barrow, Ernest T. Parker
      Pages 65-73
  5. Inhibitor Development in Hemophilia Patients

    1. Marc G. Jacquemin, Beatrijs Vanzieleghem, Jean-Marie R. Saint-Remy
      Pages 99-108
    2. Roberta Greenwood, Jeffrey Frelinger
      Pages 109-117
    3. Mark T. Reding, Huiyun Wut, Mark Krampft, David K. Okita, Brenda M. Diethelm-Okita, Nigel S. Key et al.
      Pages 119-134
  6. Back Matter
    Pages 153-182

About this book


There should be, and in the best of cases there is, a synergy between basic research and patient care. However, this synergy is hard to develop because the techniques required to be a successful researcher are so different from the skills required to be an outstanding physician. Harold R. Roberts, M.D., of the University of North Carolina at Chapel Hill, is an example of a physician-researcher who has benefited from having his feet in both the world of patient care and the world of the laboratory: he has let clinical problems direct his basic research effort and conversely has adopted research advances in his care of patients. Dr. Roberts's long and continuing career has included many research and clinical advances. He was part of the first group to determine the amino acid sequence of the important thrombin inhibitor hirudin and part of the group that prepared the first cryoprecipitates which were the first alternative to plasma as therapy in hemophilia A. Dr. Roberts has made significant advances in understanding the protein chemistry behind hemophilia B; he was among the first researchers to identify some patients as not being completely deficient but instead as having measurable levels of protein and subsequently demonstrated that this protein was dysfunctional. This important advance led him to a classification scheme for patients into Cross Reacting Material (CRM) positive, negative, and reduced. Dr.


blood hemophilia immunotherapy muscle

Editors and affiliations

  • Dougald M. Monroe
    • 1
  • Ulla Hedner
    • 2
    • 3
  • Maureane R. Hoffman
    • 4
  • Claude Negrier
    • 5
  • Geoffrey F. Savidge
    • 6
  • Gilbert C. WhiteII
    • 7
  1. 1.University of North Carolina School of MedicineChapel HillUSA
  2. 2.Novo Nordisk A/SMålovDenmark
  3. 3.University of LundLundSweden
  4. 4.Duke University and Durham VA Medical CentersDurhamUSA
  5. 5.Hôpital Edouard HerriotLyonFrance
  6. 6.Guys’ and St. Thomas’s TrustLondonUK
  7. 7.University of North Carolina School of MedicineChapel HillUSA

Bibliographic information

  • DOI
  • Copyright Information Springer Science+Business Media New York 2001
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-5474-1
  • Online ISBN 978-1-4615-1277-6
  • Series Print ISSN 0065-2598
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Internal Medicine & Dermatology